ATRA Atara Biotherapeutics, Inc. Stock Quote

ATRA [NASD]

Index	-	P/E	-	EPS (ttm)	-3.86	Insider Own	1.20%	Shs Outstand	91.46M	Perf Week	-5.77%
Market Cap	1.06B	Forward P/E	-	EPS next Y	-3.43	Insider Trans	-5.44%	Shs Float	81.54M	Perf Month	-3.85%
Income	-311.40M	PEG	-	EPS next Q	-0.90	Inst Own	-	Short Float	15.33%	Perf Quarter	-36.10%
Sales	3.60M	P/S	293.27	EPS this Y	26.90%	Inst Trans	0.27%	Short Ratio	13.47	Perf Half Y	-4.61%
Book/sh	4.36	P/B	3.04	EPS next Y	4.70%	ROA	-63.80%	Target Price	-	Perf Year	30.57%
Cash/sh	5.46	P/C	2.43	EPS next 5Y	-	ROE	-78.00%	52W Range	8.90 - 28.20	Perf YTD	-32.55%
Dividend	-	P/FCF	-	EPS past 5Y	-13.10%	ROI	-	52W High	-53.05%	Beta	2.40
Dividend %	-	Quick Ratio	5.50	Sales past 5Y	-	Gross Margin	-	52W Low	48.76%	ATR	0.68
Employees	480	Current Ratio	5.50	Sales Q/Q	-	Oper. Margin	-	RSI (14)	40.01	Volatility	5.95% 4.80%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	28.70%	Profit Margin	-	Rel Volume	0.56	Prev Close	13.59
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 04 AMC	Payout	-	Avg Volume	927.89K	Price	13.24
Recom	1.90	SMA20	-4.44%	SMA50	-10.77%	SMA200	-19.25%	Volume	524,314	Change	-2.58%

Dec-09-20

Downgrade

Citigroup

Buy → Neutral

$20 → $27

Dec-08-20

Reiterated

H.C. Wainwright

Buy

$28 → $31

Nov-10-20

Reiterated

H.C. Wainwright

Buy

$26 → $28

Jun-30-20

Initiated

Evercore ISI

Outperform

Jun-15-20

Initiated

H.C. Wainwright

Buy

$25

Apr-23-20

Upgrade

Citigroup

Neutral → Buy

$14

Nov-08-19

Downgrade

JP Morgan

Overweight → Neutral

$43 → $22

Sep-27-19

Downgrade

Goldman

Neutral → Sell

$14 → $9

Sep-16-19

Downgrade

Jefferies

Buy → Hold

$32 → $15

Jun-04-19

Upgrade

Citigroup

Sell → Neutral

$23 → $24

May-30-19

Initiated

ROTH Capital

Buy

May-23-19

Initiated

Stifel

Buy

Jan-23-19

Initiated

Mizuho

Buy

Apr-10-18

Initiated

JP Morgan

Overweight

$56

Mar-16-18

Initiated

Guggenheim

Neutral

Mar-05-18

Reiterated

Jefferies

Buy

$30 → $46

Feb-28-18

Downgrade

JMP Securities

Mkt Outperform → Mkt Perform

Feb-15-18

Downgrade

Citigroup

Neutral → Sell

Jan-03-18

Upgrade

Citigroup

Sell → Neutral

Oct-06-17

Resumed

Goldman

Neutral

May-10-21 08:30AM	Atara Biotherapeutics Names Cell Therapy & Oncology Leader Cokey Nguyen, Ph.D. as Chief Scientific Officer Business Wire
May-07-21 04:01PM	Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire +5.43%
May-04-21 05:20PM	Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates Zacks
04:01PM	Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress Business Wire
02:30PM	Atara Biotherapeutics, Inc. to Host Earnings Call ACCESSWIRE
Apr-27-21 05:51PM	Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021 Business Wire
Apr-26-21 01:17AM	Is ATRA Stock A Buy or Sell? Insider Monkey
Apr-02-21 04:35PM	Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire
Mar-21-21 03:58AM	We're Hopeful That Atara Biotherapeutics (NASDAQ:ATRA) Will Use Its Cash Wisely Simply Wall St.
Mar-14-21 04:00PM	Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting Business Wire
Mar-09-21 04:01PM	Atara Biotherapeutics to Participate in Virtual 33rd Annual ROTH Conference Business Wire
Mar-05-21 04:01PM	Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire
Mar-02-21 09:30AM	Atara Biotherapeutics Inc (ATRA) Q4 2020 Earnings Call Transcript Motley Fool
Mar-01-21 04:05PM	Atara Biotherapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Operational Progress Business Wire
02:30PM	Atara Biotherapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-18-21 04:01PM	Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021 Business Wire
Feb-08-21 09:00AM	Atara Biotherapeutics Presents Key Data for Advancing the Development of Tab-cel® and ATA188 at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience Business Wire
Jan-19-21 04:14PM	Atara Biotherapeutics to Present Data at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience Business Wire
Jan-10-21 04:06PM	Atara Biotherapeutics Will Present Recent Advancements and Key Upcoming Milestones at the 39th Annual J.P. Morgan Healthcare Conference Business Wire
Jan-06-21 08:30AM	Atara Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference Business Wire
Jan-04-21 07:30AM	Atara Biotherapeutics Provides Regulatory Update for Tab-Cel® for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease Business Wire
Dec-08-20 09:26PM	Atara Biotherapeutics Announces Pricing of $175.0 Million Public Offering Business Wire
Dec-07-20 04:07PM	Atara Biotherapeutics Announces Proposed Offering of Common Stock Business Wire +6.67%
09:13AM	Bayer (BAYRY) Inks Deal With Atara for CAR-T Cell Therapies Zacks
07:00AM	Atara Biotherapeutics Presents First Preclinical Evaluation of ATA3219, a Next-Generation Allogeneic CD19 CAR T Cell Therapy, at the 62nd American Society of Hematology (ASH) Annual Meeting Business Wire
Dec-06-20 11:00PM	Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors Business Wire
Nov-16-20 04:01PM	Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences Business Wire +8.20%
Nov-15-20 10:00AM	Atara Biotherapeutics to Present New Open-Label Extension Data, Including 15-Month Safety and Efficacy Data from Highest Dose Cohorts, in the Phase1a Study of ATA188 for Progressive Forms of Multiple Sclerosis at the ECF 28th Annual Meeting Business Wire
Nov-13-20 10:31AM	Atara Biotherapeutics Moves With Rising Relative Price Strength Investor's Business Daily
Nov-12-20 08:30AM	Atara Biotherapeutics Presents New Preclinical Data on ATA3271, a Next-Generation Allogeneic Mesothelin-Targeted CAR T to Treat Solid Tumors, at the 35th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020) Business Wire +15.12%
Nov-10-20 10:30AM	Atara Biotherapeutics Inc (ATRA) Q3 2020 Earnings Call Transcript Motley Fool +8.19%
Nov-09-20 04:01PM	Atara Biotherapeutics Announces Third Quarter 2020 Financial Results and Operational Progress Business Wire +7.06%
02:45PM	Atara Biotherapeutics, Inc. to Host Earnings Call ACCESSWIRE
Nov-08-20 12:47PM	The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga
Nov-02-20 04:01PM	Atara Biotherapeutics to Announce Third Quarter 2020 Financial Results on Monday, November 9, 2020 Business Wire
Oct-06-20 10:08PM	Hedge Funds Are Crazy About Atara Biotherapeutics Inc (ATRA) Insider Monkey
Sep-22-20 07:11AM	We Think Atara Biotherapeutics (NASDAQ:ATRA) Needs To Drive Business Growth Carefully Simply Wall St.
Sep-16-20 12:19PM	Stocks Showing Market Leadership: Atara Biotherapeutics Earns 92 RS Rating Investor's Business Daily
Sep-14-20 09:28AM	Company News for Sep 14, 2020 Zacks
08:47AM	Atara (ATRA) Looks Good: Stock Adds 5.1% in Session Zacks
08:30AM	Atara Biotherapeutics To Present Clinical Data in Epstein-Barr Virus-Driven (EBV+) Acquired & Primary Immunodeficiency Lymphoproliferative Diseases (AID-LPD and PID-LPD) from Tab-Cel® Expanded Access Program in e-Poster at ESMO 2020 Virtual Congress Business Wire
Sep-13-20 05:15AM	Atara Bio Rises After Multiple Sclerosis Drug Shows Sustained Improvement SmarterAnalyst
Sep-11-20 08:00AM	Atara Biotherapeutics Announces All Progressive Multiple Sclerosis Patients with Sustained Disability Improvement at Six Months Confirmed Improvement at 12 Months in the Phase 1a Study of ATA188 Business Wire +5.06%
Sep-09-20 09:36AM	Billionaire David Shaw Pours Money Into 3 Strong Buy Stocks TipRanks +10.18%
Sep-08-20 07:00AM	Atara Biotherapeutics Announces FDA Clearance of IND for ATA2271, a Next-Generation Autologous Mesothelin-Targeted CAR T with Novel PD1DNR and 1XX Technologies Combined to Treat Solid Tumors Business Wire
Sep-01-20 07:00AM	Atara Biotherapeutics to Present 12-Month Data from All Four Cohorts in the Phase 1a Study of ATA188 in Progressive Multiple Sclerosis at MSVirtual2020 Business Wire
Aug-12-20 09:53AM	Did Hedge Funds Make The Right Call On Atara Biotherapeutics Inc (ATRA) ? Insider Monkey
Aug-05-20 04:01PM	Atara Biotherapeutics Announces Second Quarter 2020 Financial Results and Operational Progress Business Wire
Aug-04-20 08:19AM	Why Atara Biotherapeutics (ATRA) Might Surprise This Earnings Season Zacks -8.77%
Jul-29-20 04:01PM	Atara Biotherapeutics to Announce Second Quarter 2020 Financial Results on Wednesday, August 5, 2020 Business Wire
Jul-21-20 12:00PM	Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade Zacks
Jul-01-20 11:28AM	Will Atara Biotherapeutics Continue to Surge Higher? Zacks
07:12AM	2 Biotech Stocks That Could Soar in 2020 Motley Fool
Jun-30-20 10:19AM	Benzinga's Top Upgrades, Downgrades For June 30, 2020 Benzinga +5.27%
Jun-24-20 04:34PM	Atara Biotherapeutics Announces Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire +5.47%
Jun-23-20 09:48PM	Hedge Funds Have Never Been This Bullish On Atara Biotherapeutics Inc (ATRA) Insider Monkey
10:13AM	Is Atara Biotherapeutics (ATRA) Stock a Solid Choice Right Now? Zacks
Jun-17-20 08:47AM	Atara Biotherapeutics Announces First Patient Enrolled in Randomized Placebo-Controlled Study of Allogeneic T-cell Therapy ATA188 in Progressive Forms of Multiple Sclerosis Business Wire
Jun-15-20 09:57AM	Benzinga's Top Upgrades, Downgrades For June 15, 2020 Benzinga +11.47%
Jun-05-20 04:15PM	Atara Biotherapeutics Announces its 2020 Annual Meeting of Stockholders Will Be Held on June 16, 2020 in Virtual Format Business Wire
Jun-04-20 04:01PM	Atara Biotherapeutics to Participate at Two Upcoming Conferences Business Wire -8.56%
May-27-20 01:16AM	Atara Biotherapeutics Announces Pricing of $175.5 Million Public Offering Business Wire
May-26-20 04:05PM	Atara Biotherapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants Business Wire -23.57%
07:00AM	Atara Biotherapeutics Presents Data Demonstrating Safety & Sustained Disability Improvement at 12 Months with ATA188 in Patients with Progressive Multiple Sclerosis in Late-Breaking e-Poster at the 2020 European Academy of Neurology Virtual Congress Business Wire
May-19-20 08:30AM	Atara Biotherapeutics to Present Late-Breaking ATA188 Data in Progressive Multiple Sclerosis at 2020 European Academy of Neurology (EAN) Virtual Congress Business Wire
May-18-20 04:30PM	Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire
12:00PM	Atara Biotherapeutics (ATRA) Moves to Strong Buy: Rationale Behind the Upgrade Zacks
May-15-20 09:38AM	Atara Biotherapeutics Announces Presentation of Late-Breaking Preclinical Data on ATA2271, a Next-Generation Autologous CAR T Immunotherapy Targeting Mesothelin, at the American Association for Cancer Research (AACR) Virtual Annual Meeting II 2020 Business Wire +12.37%
May-14-20 04:05PM	Atara Biotherapeutics Names Cell Therapy & Oncology Leader Jakob Dupont, M.D. as Global Head of Research & Development Business Wire -7.53%
May-13-20 09:21AM	Why Atara Biotherapeutics (ATRA) Stock Might be a Great Pick Zacks
May-11-20 04:01PM	Atara Biotherapeutics Announces Appointment of Cell & Gene Therapy Expert Maria Grazia Roncarolo, MD to Board of Directors Business Wire
11:25AM	Will Atara Biotherapeutics Continue to Surge Higher? Zacks
May-08-20 04:12AM	Edited Transcript of ATRA earnings conference call or presentation 6-May-20 8:30pm GMT Thomson Reuters StreetEvents +10.82%
May-07-20 02:00PM	Atara Biotherapeutics Inc (ATRA) Q1 2020 Earnings Call Transcript Motley Fool +7.65%
May-06-20 04:01PM	Atara Biotherapeutics Announces First Quarter 2020 Financial Results and Operational Progress Business Wire
Apr-30-20 04:01PM	Atara Biotherapeutics to Announce First Quarter 2020 Financial Results on Wednesday, May 6, 2020 Business Wire
08:30AM	Atara Biotherapeutics Appoints Biotech and Finance Industry Veteran Ron Renaud as Non-Executive Chair of the Board of Directors Business Wire
Apr-22-20 08:30PM	Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire
Apr-14-20 04:41PM	Seth Klarman Dials Down Akebia Therapeutics Stake GuruFocus.com +5.58%
Apr-02-20 08:33AM	Company Profile for Atara Biotherapeutics, Inc. Business Wire +5.14%
08:30AM	Atara Biotherapeutics Provides Update in Context of COVID-19 Pandemic Business Wire
Mar-26-20 10:19AM	Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Deliver On Growth Plans? Simply Wall St. +6.76%
Feb-28-20 07:04AM	Edited Transcript of ATRA earnings conference call or presentation 27-Feb-20 1:00pm GMT Thomson Reuters StreetEvents +5.84%
Feb-27-20 07:35AM	The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy Benzinga
07:30AM	Atara Biotherapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Recent Clinical, Operational and Strategic Progress GlobeNewswire
06:00AM	Atara Biotherapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-21-20 04:00PM	Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire
Feb-20-20 04:00PM	Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences GlobeNewswire -8.40%
Feb-19-20 04:00PM	Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020 GlobeNewswire
Feb-05-20 08:30AM	Atara Biotherapeutics Names Kristin Yarema as Chief Commercial Officer GlobeNewswire +7.09%
Jan-12-20 02:00PM	Atara Biotherapeutics to Present 2020 Key Milestones and Progress in Bringing Off-The-Shelf, Allogeneic T-Cell Immunotherapies to Patients in Need at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-24-19 10:10AM	Trade Deal Optimism Fuels Santa Rally: ETFs & Stocks to Bet On Zacks +5.33%
Dec-18-19 07:59AM	5 Beaten-Down Biotech Stocks Set to Rebound in 2020 Zacks
Dec-11-19 11:04PM	Hedge Funds Have Never Been More Bullish On Atara Biotherapeutics Inc (ATRA) Insider Monkey +5.51%
Dec-10-19 12:22PM	Seth Klarman Pares Paratek Pharmaceuticals Stake GuruFocus.com
Dec-09-19 10:00AM	Atara Biotherapeutics Reports Updated Long-Term Clinical Results from a Tab-cel® Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Nov-26-19 04:00PM	Atara Biotherapeutics to Participate at Evercore ISI Second Annual HealthCONx Conference GlobeNewswire
Nov-12-19 09:00AM	Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's Why Zacks
Nov-08-19 05:02AM	Edited Transcript of ATRA earnings conference call or presentation 7-Nov-19 1:00pm GMT Thomson Reuters StreetEvents
Nov-07-19 07:30AM	Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress GlobeNewswire +11.18%

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA2321 for acute myeloid leukemia; and ATA368 for human papillomavirus. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Newell Joe	Chief Operations Officer	Apr 05	Sale	14.74	655	9,655	134,924	Apr 07 04:36 PM
Newell Joe	Chief Operations Officer	Mar 26	Sale	14.58	2,640	38,491	135,579	Mar 30 05:18 PM
Koppikar Utpal	Chief Financial Officer	Mar 26	Sale	14.58	1,761	25,675	172,582	Mar 30 05:19 PM
Newell Joe	Chief Operations Officer	Mar 15	Option Exercise	12.15	3,500	42,525	145,219	Mar 15 07:25 PM
Newell Joe	Chief Operations Officer	Mar 15	Sale	17.41	7,000	121,870	138,219	Mar 15 07:25 PM
Newell Joe	Chief Operations Officer	Mar 02	Sale	16.74	1,665	27,872	141,719	Mar 04 04:08 PM
Touchon Pascal	President and CEO	Mar 02	Sale	16.74	4,887	81,808	367,621	Mar 04 04:06 PM
Koppikar Utpal	Chief Financial Officer	Mar 02	Sale	16.74	1,461	24,457	174,343	Mar 04 04:07 PM
Koppikar Utpal	Chief Financial Officer	Feb 08	Sale	20.39	1,759	35,866	130,546	Feb 09 07:59 PM
Newell Joe	Chief Operations Officer	Feb 08	Sale	20.39	3,886	79,236	105,669	Feb 09 07:59 PM
Newell Joe	Chief Operations Officer	Jan 15	Option Exercise	12.15	3,500	42,525	116,555	Jan 19 04:02 PM
Newell Joe	Chief Operations Officer	Jan 15	Sale	18.84	7,000	131,880	109,555	Jan 19 04:02 PM
Newell Joe	Chief Operations Officer	Dec 16	Option Exercise	12.15	3,500	42,525	120,055	Dec 18 06:35 PM
Newell Joe	Chief Operations Officer	Dec 16	Sale	23.11	7,000	161,735	113,055	Dec 18 06:35 PM
Newell Joe	Chief Operations Officer	Nov 17	Sale	19.77	1,648	32,588	116,555	Nov 18 04:07 PM
Koppikar Utpal	Chief Financial Officer	Nov 17	Sale	19.77	1,469	29,048	132,061	Nov 18 04:08 PM
Touchon Pascal	President and CEO	Nov 17	Sale	19.77	4,716	93,254	255,321	Nov 18 04:07 PM
Newell Joe	Chief Operations Officer	Nov 13	Option Exercise	12.15	3,500	42,525	125,703	Nov 16 04:19 PM
Newell Joe	Chief Operations Officer	Nov 13	Sale	18.49	7,500	138,688	118,203	Nov 16 04:19 PM
Touchon Pascal	President and CEO	Aug 18	Sale	12.09	4,807	58,117	260,037	Aug 20 07:39 PM
Koppikar Utpal	Chief Financial Officer	Aug 18	Sale	12.09	1,496	18,087	133,530	Aug 20 07:38 PM
Newell Joe	Chief Operations Officer	Aug 18	Sale	12.09	1,678	20,287	122,203	Aug 20 07:37 PM
Touchon Pascal	President and CEO	Jun 25	Sale	12.92	12,135	156,784	264,844	Jun 26 04:18 PM
Koppikar Utpal	Chief Financial Officer	Jun 09	Sale	10.18	3,924	39,946	135,026	Jun 10 04:05 PM
Newell Joe	Chief Operations Officer	May 18	Sale	11.22	1,603	17,986	123,881	May 20 06:11 PM
Koppikar Utpal	Chief Financial Officer	May 18	Sale	11.22	1,428	16,022	137,375	May 20 06:11 PM
Touchon Pascal	President and CEO	May 18	Sale	11.22	3,195	35,848	276,979	May 20 06:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience